Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma Meeting Abstract
| Authors: | Einsele, H.; Parekh, S.; Madduri, D.; Santomasso, B.; Pérez-Larraya, J. G.; van de Donk, N. W.C.J.; Arnulf, B.; Mateos, M. V.; De Braganca, K. C.; Varsos, H.; Carrasco-Alfonso, M. J.; Akram, M.; Lendvai, N.; Jackson, C. C.; Olyslager, Y.; Zudaire, E.; Li, C.; Geng, D.; Jakubowiak, A.; Cohen, A. |
| Abstract Title: | Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma |
| Meeting Title: | 18th International Myeloma Workshop (IMW) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-10-01 |
| Start Page: | S120 |
| End Page: | S121 |
| Language: | English |
| ACCESSION: | WOS:000717640800209 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)02282-5 |
| Notes: | Meeting Abstract: P-155 -- Source: Wos |
